Experts believe that further studies will enhance the onset of rapid and positive drug effects along with reliable and safe health delivery systems. Therefore, clinical trials on marijuana for symptom management and other medical uses should be supported and conducted in order to achieve the goal of determining its accurate therapeutic value, if there is.
The last sixteen years of cannabinoid studies created impacts on the medical and pharmaceutical industries, patients, families, adolescent people, health care providers and policymakers. The accumulated data evoked the wide-range of public opinions and indications that consequently led people to divide. Some insist that there have been false claims about medical marijuana which is the reason why its application as medicine has been prohibited from patients. They justified that, scientific evidence presented various indications, specifically for pain relief, appetite stimulation and antiemesis. Clients like those with AIDS or cancer, for example, undergoing chemotherapy and continue to experience appetite loss, severe pain and nausea, cannabinoid drugs possibly help relief. However, others strongly argued that cannabinoid drugs still pose a high level of health risks.
Voters from Arizona and California submitted referenda in November of 1996, in order to allow the use of marijuana as medicine. After five months, Arizona’s referendum was invalidated that subsequently startled national response. The National Drug Control Policy (ONDCP) in January 1997, commissioned the Institute of Medicine (IOM) to conduct a thorough review on various scientific evidence to carefully evaluate marijuana and its constituent cannabinoids potential health benefits as well as risks.